Home / Products / Formulations / Svizera Healthcare / Ace / Clofert
 

CLOFERT:

 
 
 
   
   
   
 
 


 
   
 
     
     
 
  Composition :
   
  Each tablet of CLOFERT-25 / 50 / 100 contains:
Clomifene citrate…25 / 50 100 mg
   
   
  Therapeutic Indications & Usage
   
  CLOFERT is indicated for treatment of ovulatory dysfunction in women desiring pregnancy. Patients expected to achieve success with clomifene (CLOFERT) therapy include those with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
   
   
  Contraindications
   
  CLOFERT is not advocated for those hypersensitive to its ingredients. It is not to be given in pregnant & lactating females, presence of abnormal uterine bleeding of undetermined etiology, ovarian cysts or enlargement not due to polycystic ovarian disease, active or past history of liver disease, uncontrolled thyroid or adrenal function, or organic intracranial lesion.
   
   
  Precautions
   
  CLOFERT is recommended only if the following criteria are met: patient is not pregnant, absence of ovarian cysts and abnormal vaginal bleeding, and normal liver function present.
   
  To minimize the hazard associated with occasional abnormal ovarian enlargement associated with CLOFERT, the lowest dose of clomifene consistent with expected results should be advocated. If enlargement of ovary occurs, additional CLOFERT therapy should not be given until the ovaries have returned to pretreatment size, or alternatively the dosage and duration of next course should be reduced. Polycystic ovarian disease patients must be started with the lowest dose of CLOFERT, and shortest treatment duration for the first course must be given. If ovarian cysts do not regress spontaneously, a thorough evaluation should be performed to rule out presence of ovarian neoplasia.
   
   
  Warnings
   
  There is increased chance of multiple pregnancies when conception occurs in relation to clomifene (CLOFERT) therapy. Moreover, in those successfully impregnated, there is increased risk of spontaneous abortion and stillbirth.
   
  Visual symptoms which may occur during clomifene (CLOFERT) therapy may render activities such as driving and operating machinery more hazardous than usual, particularly under conditions of variable lighting. CLOFERT must be discontinued in those experiencing any visual symptoms, and a complete ophthalmological check up needs to be carried out.
   
   
  Adverse Reactions
   
  The common adverse reactions to clomifene (CLOFERT) include ovarian enlargement, vasomotor flushes, gastrointestinal intolerance, breast discomfort, visual disturbances, headache and abnormal uterine bleeding.
   
  Infrequently clomifene (CLOFERT) may cause hypersensitivity reactions, appetite & weight changes, dizziness, fatigue, hair loss / dry hair, urinary complaints, insomnia, light-headedness, nervous tension, vaginal dryness and vertigo.
   
   
  Recommended Dosage & Administration
   
  Anovulatory infertility:
  1 CLOFERT-50 Tab once daily for 5 days. Increase the dose in those who do not respond to cyclic therapy to 1 CLOFERT-100 Tab once daily for 5 days during the next cycle.
   
  The second course can be started as early as 30 days after the previous one provided pregnancy has been excluded.
   
  Coitus must be timed with the expected time of ovulation; appropriate tests to determine ovulation are useful at this time.
   
  Male Infertility:
  1 CLOFERT-25 Tab for 25days; repeat after 5days as necessary.
   
   
  Presentations
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
         
 
"Maneesh" Pharmaceuticals   |  Manufacturing Excellence  |   International Presence  |  Products
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh